Innate Pharma Valuation
Is IDD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Future Cash Flow Value
Significantly Below Future Cash Flow Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Future Cash Flow Value
What is the Fair Price of IDD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Ultimate guide to DCF valuation for stock investing
Learn how to determine fair value like the best investors in the world.
Below Future Cash Flow Value: IDD (€1.77) is trading above our estimate of future cash flow value (€0.8)
Significantly Below Future Cash Flow Value: IDD is trading above our estimate of future cash flow value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IDD?
Key metric: As IDD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is IDD's PS Ratio? | |
|---|---|
| PS Ratio | 17.1x |
| Sales | €9.01m |
| Market Cap | €153.88m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 15.8x |
| Enterprise Value/EBITDA | -2.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does IDD's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 24.8x | ||
HPHA Heidelberg Pharma | 49.2x | 85.93% | €130.5m |
LQ0 Dextech Medical | 41x | n/a | €184.9m |
7V0 Darwin | 1.1x | 25.83% | €74.4m |
FYB Formycon | 8x | 36.63% | €354.3m |
IDD Innate Pharma | 17.1x | 46.02% | €153.9m |
Price-To-Sales vs Peers: IDD is good value based on its Price-To-Sales Ratio (17.1x) compared to the peer average (24.8x).
Historical Price to Sales Ratio
Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.
Fetching historical data
Price to Sales Ratio vs Industry
How does IDD's PS Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Sales vs Industry: IDD is expensive based on its Price-To-Sales Ratio (17.1x) compared to the European Biotechs industry average (8.6x).
Price to Sales Ratio vs Fair Ratio
What is IDD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 17.1x |
| Fair PS Ratio | 0.008x |
Price-To-Sales vs Fair Ratio: IDD is expensive based on its Price-To-Sales Ratio (17.1x) compared to the estimated Fair Price-To-Sales Ratio (0x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.77 | €5.35 +202.94% | 15.89% | €6.20 | €4.50 | n/a | 2 |
| May ’27 | €1.18 | €5.35 +352.62% | 15.89% | €6.20 | €4.50 | n/a | 2 |
| Apr ’27 | €1.09 | €5.35 +390.83% | 15.89% | €6.20 | €4.50 | n/a | 2 |
| Feb ’27 | €1.53 | €6.15 +300.91% | 0.81% | €6.20 | €6.10 | n/a | 2 |
| Jan ’27 | €1.52 | €4.90 +222.57% | 36.21% | €6.20 | €2.39 | n/a | 3 |
| Dec ’26 | €1.71 | €4.90 +186.02% | 36.21% | €6.20 | €2.39 | n/a | 3 |
| Nov ’26 | €1.71 | €4.84 +183.90% | 38.16% | €6.20 | €2.23 | n/a | 3 |
| Oct ’26 | €1.69 | €4.93 +191.72% | 35.01% | €6.20 | €2.49 | n/a | 3 |
| Sep ’26 | €1.81 | €4.35 +139.79% | 42.69% | €6.20 | €2.49 | n/a | 2 |
| Aug ’26 | €1.84 | €4.35 +135.88% | 42.69% | €6.20 | €2.49 | n/a | 2 |
| Jul ’26 | €1.51 | €4.80 +218.50% | 34.27% | €6.20 | €2.49 | n/a | 3 |
| Jun ’26 | €1.95 | €5.70 +191.88% | 37.07% | €8.40 | €2.49 | n/a | 4 |
| May ’26 | €1.84 | €6.15 +233.66% | 34.54% | €8.40 | €2.43 | €1.18 | 5 |
| Apr ’26 | €1.79 | €6.14 +243.51% | 34.67% | €8.40 | €2.41 | €1.09 | 5 |
| Mar ’26 | €2.04 | €6.14 +201.08% | 34.67% | €8.40 | €2.41 | €1.48 | 5 |
| Feb ’26 | €1.72 | €6.14 +257.51% | 34.67% | €8.40 | €2.41 | €1.53 | 5 |
| Jan ’26 | €1.94 | €6.14 +216.60% | 34.67% | €8.40 | €2.41 | €1.52 | 5 |
| Dec ’25 | €1.42 | €6.14 +332.54% | 34.67% | €8.40 | €2.41 | €1.71 | 5 |
| Nov ’25 | €1.67 | €6.11 +266.31% | 35.78% | €8.40 | €2.25 | €1.71 | 5 |
| Oct ’25 | €1.97 | €6.21 +215.04% | 39.17% | €8.40 | €2.25 | €1.69 | 4 |
| Sep ’25 | €2.07 | €6.28 +203.14% | 37.16% | €8.40 | €2.50 | €1.81 | 4 |
| Aug ’25 | €2.01 | €6.28 +212.19% | 37.16% | €8.40 | €2.50 | €1.84 | 4 |
| Jul ’25 | €1.84 | €6.48 +251.52% | 36.31% | €8.40 | €2.50 | €1.51 | 4 |
| Jun ’25 | €2.54 | €6.32 +148.82% | 33.63% | €8.40 | €2.50 | €1.95 | 5 |
| May ’25 | €2.20 | €6.27 +185.65% | 35.34% | €8.40 | €2.25 | €1.84 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 05:00 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innate Pharma S.A. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Yigal Nochomovitz | Citigroup Inc |